Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejca.2020.07.009 http://scihub22266oqcxt.onion/10.1016/j.ejca.2020.07.009 32805640!7383132!32805640     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32805640&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Cancer 2020 ; 137 (?): 235-239 Nephropedia Template TP {{tp|p=32805640|t=2020. Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?|pdf=|usr=}}{{32805640}} gab.com Text Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management JO: Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32805640 #FOAvip The outbreak of the Coronavirus disease (COVID-19) pandemic has deeply challenged healthcare systems and care of patients with cancer. Phase 1 studies are among the most complicated clinical trials and require thorough patient selection, as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of phase 1 trials and management of COVID-19-positive patients with cancer enrolled in such trials. We notably present the risks and challenges raised by COVID-19-infected phase 1 patients, in terms of safety, toxicity causality assessment, drug efficacy evaluation and clinical research priorities. We finally propose some guidelines for the conduct of phase 1 trials and management of COVID-19-infected patients in a pandemic time. Twit Text FOAVip Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management ????Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=32805640 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32805640 #FOAvip English Wikipedia <ref>{{Cite pmid|32805640}}</ref> Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management? #MMPMID32805640 Postel-Vinay S; Massard C; Soria JC Eur J Cancer 2020[Sep]; 137 (?): 235-239 PMID32805640show ga The outbreak of the Coronavirus disease (COVID-19) pandemic has deeply challenged healthcare systems and care of patients with cancer. Phase 1 studies are among the most complicated clinical trials and require thorough patient selection, as well as intensive patient monitoring. In this perspective, we discuss the key factors that should be considered for the conduct of phase 1 trials and management of COVID-19-positive patients with cancer enrolled in such trials. We notably present the risks and challenges raised by COVID-19-infected phase 1 patients, in terms of safety, toxicity causality assessment, drug efficacy evaluation and clinical research priorities. We finally propose some guidelines for the conduct of phase 1 trials and management of COVID-19-infected patients in a pandemic time. |*Patient Selection[MESH] |Antineoplastic Agents/*adverse effects[MESH] |Betacoronavirus/immunology/isolation & purification[MESH] |COVID-19[MESH] |Clinical Trials, Phase I as Topic/*standards[MESH] |Coronavirus Infections/epidemiology/immunology/*therapy/virology[MESH] |Evidence-Based Medicine/standards[MESH] |Humans[MESH] |Infection Control/standards[MESH] |Medical Oncology/standards[MESH] |Neoplasms/*drug therapy/immunology[MESH] |Pandemics[MESH] |Pneumonia, Viral/epidemiology/immunology/*therapy/virology[MESH] |Practice Guidelines as Topic[MESH] |SARS-CoV-2[MESH]Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we (epmc).pdf DeepDyve Pubget Overpricing